Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2015-12-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to make asset impairment provisions, including detailed amounts and the rationale behind these provisions. It includes statements from the board, audit committee, independent directors, and supervisory board, confirming the appropriateness and compliance of the impairment. The document is relatively short (1970 characters) and focuses on a specific accounting action rather than presenting a full financial report or comprehensive financial statements. It does not contain full financial data or a complete financial report but rather an announcement of a specific financial event and related approvals. Therefore, it fits best as a Regulatory Filing (RNS) rather than a full Annual Report (10-K), Interim Report (IR), or Audit Report (AR).
2015-12-02 Chinese
第七届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the approval of asset impairment provisions and accounting policy improvements. It is a formal announcement of board decisions rather than a full financial report or audit report. The document is short (688 characters) and does not contain detailed financial statements or comprehensive analysis. It is not a report publication announcement since it contains substantive content of the board's resolutions. The content fits best under Board/Management Information (MANG) as it relates to internal governance decisions by the supervisory board.
2015-12-02 Chinese
拟股权转让涉及的新疆爱迪新能源科技有限公司股东全部权益价值评估报告
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for the entire equity of Xinjiang Aidi New Energy Technology Co., Ltd., commissioned by Jiangsu Sihuan Biological Co., Ltd. It includes a registered asset appraiser's statement, a summary, detailed valuation methods, asset and liability listings, legal and regulatory references, and specific valuation conclusions. The report is prepared in accordance with asset evaluation standards and is intended to provide a market value reference for a proposed equity transfer. It contains substantive financial data, valuation methodology, and legal disclosures. This is a standalone asset valuation report related to a capital transaction (equity transfer). It is not an announcement, certification, or a general regulatory filing. It is not a full annual or interim financial report, nor a management discussion or earnings release. The closest fitting category is Audit Report / Information (AR), as it is a specialized valuation report prepared by certified appraisers, including audited financial data and valuation conclusions, but not a full annual report or earnings release. Therefore, the document should be classified as AR with high confidence. Q3 2015
2015-12-02 Chinese
独立董事意见
Board/Management Information Classification · 95% confidence The document is titled 'Independent Directors' Opinions' and discusses independent opinions on asset impairment provisions, accounting policy improvements, and the sale of a controlling subsidiary's equity. It includes statements about compliance with laws and protection of shareholder interests. The content is focused on governance and oversight matters rather than full financial statements or earnings data. The document length is short (696 characters), and it does not contain comprehensive financial data or detailed financial results. It is not an announcement of a report but an opinion statement from independent directors. This fits best under Board/Management Information (MANG), as it relates to board-level opinions and approvals on significant company matters.
2015-12-02 Chinese
关于出售控股子公司股权公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the sale of controlling equity in a subsidiary company by Jiangsu Sihuan Bioengineering Co., Ltd. It includes transaction details, parties involved, asset valuations, audit and assessment reports, board approvals, and independent director opinions. The document is not a full annual or interim financial report but rather a specific transaction announcement related to capital structure changes. It does not contain comprehensive financial statements or quarterly results but focuses on the sale of subsidiary shares and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4376 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2015-12-02 Chinese
关于完善会计政策的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the improvement and supplementation of its accounting policies, specifically related to biological assets. It references regulatory guidelines from the China Securities Regulatory Commission and details the board and independent directors' approval of these accounting policy changes. The document does not contain financial statements or substantive financial data but rather explains the policy changes and their rationale. It is a formal announcement about accounting policy changes, not a full financial report or audit report. Given the nature of the content and the absence of financial data, this fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2015-12-02 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.